Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization -9% Improvement Relative Risk c19early.org/m Tazare et al. Molnupiravir for COVID-19 EARLY Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 68,640 patients in the United Kingdom (Dec 2021 - May 2022) No significant difference in death/hosp. Tazare et al., medRxiv, doi:10.1101/2023.05.12.23289914 Favors molnupiravir Favors control
Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform
Tazare et al., medRxiv, doi:10.1101/2023.05.12.23289914 (Preprint)
Tazare et al., Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2.., medRxiv, doi:10.1101/2023.05.12.23289914 (Preprint)
May 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
OpenSAFELY retrospective 75,048 outpatients in the UK, using the clone-censor-weight approach to address immortal time bias, showing no significant difference in combined mortality/hospitalization with molnupiravir treatment.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, twitter.com] for analysis of variants potentially created by molnupiravir.
This study includes molnupiravir and sotrovimab.
risk of death/hospitalization, 9.0% higher, HR 1.09, p = 0.28, treatment 3,072, control 65,568.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tazare et al., 16 May 2023, retrospective, United Kingdom, preprint, 31 authors, study period 16 December, 2021 - 21 May, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit